Qualigen Therapeutics secures global patents for cancer drug QN-302

Published 16/07/2025, 13:12
Qualigen Therapeutics secures global patents for cancer drug QN-302

CARLSBAD, Calif. - Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a small-cap biotech with a market capitalization of $5.77 million, announced Wednesday that it has secured multiple patents for its cancer drug QN-302 across Europe, India, China, and Russia during the first half of 2025. According to InvestingPro analysis, the company maintains a healthy balance sheet with cash exceeding debt levels.

The patents, titled "Substituted Naphthalene Diimides and Their Use," cover the product and its manufacturing methods for QN-302, a drug developed by Professor Stephen Neidle and his team at University College London and licensed by Qualigen.

The patent protection extends into 2040 and covers more than 20 European countries, representing the majority of Europe’s population. Similar patent coverage has been granted in India, China, and Russia.

"Having the patents granted covering so much of the world’s population strengthens our position as a drug development company," said Kevin Richardson II, CEO of Qualigen. "By assuring such strong coverage will allow us to continue bringing QN-302 to market and treating patients suffering from Pancreatic and Gastrointestinal Cancer."

QN-302 is being developed for the treatment of pancreatic and gastrointestinal cancers.

The company stated in a press release that it will provide periodic updates on new patents granted, noting that several have been published while others are pending.

In other recent news, Qualigen Therapeutics has been navigating a series of notable developments. The company disclosed that it received a deficiency notification from Nasdaq due to its failure to timely file the Quarterly Report for the period ended March 31, 2025. This delay could potentially lead to the delisting of its securities from The Nasdaq Stock Market, as it violates Nasdaq Listing Rule 5250(c)(1). Qualigen Therapeutics plans to present a strategy to regain compliance during a scheduled hearing with the Nasdaq Hearings Panel. Meanwhile, the company announced the appointment of Robert B. Lim as the new Chair of its Audit Committee, replacing Graydon Bensler. Mr. Lim is recognized as an “audit committee financial expert” and is an independent director under Nasdaq and SEC rules. These recent developments are being closely monitored by investors and stakeholders, as they could significantly impact Qualigen Therapeutics’ future on the stock exchange.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.